Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus
Completed
Novartis
Phase 4
2003-04-01
Type 2 diabetes mellitus is usually associated with high blood pressure, which is a risk
factor for kidney disease. Aggressive blood pressure reduction is an important strategy to
protect the kidney and reduce urinary protein which develops with kidney disease. This study
will evaluate the effects of amlodipine/benazepril in reducing blood pressure and urinary
protein in hypertensive subjects with type 2 diabetes mellitus.
Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension
Completed
Novartis Pharmaceuticals
Phase 4
2004-12-01
This trial is designed to study the efficacy of an amlodipine besylate/benazepril treatment
regimen versus an amlodipine treatment regimen in the treatment of severe hypertension.
Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension
Completed
Novartis
Phase 4
2004-07-01
Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and
mortality in patients with high blood pressure, compared to those without LVH. Reduction of
left ventricular mass (LVM) with antihypertensive agents is associated with improved clinical
outcome. This study will evaluate the effects of amlodipine/benazepril in reducing LVM in
patients with high risk hypertension.
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
Terminated
Novartis
Phase 3
2003-10-01
A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to
evaluate the effectiveness of the combination on reducing heart disease and death in a high
risk hypertensive population.
A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril
Terminated
Novartis Pharmaceuticals
Phase 4
2004-01-01
The purpose of this study is to evaluate the efficacy of valsartan, benazepril or the
combination of both in reduction of microalbuminuria in Type 2 diabetic patients.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
